deaths (OS)

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

versus docetaxel
pembrolizumab (2mg/kg) vs. docetaxel 2 0.64 [0.50; 0.83], 2 RCTs, I2=42% conclusive
low degree of certainty